Washington: Dr. Hisham bin Saad Aljadhey, the CEO of the Saudi Food and Drug Authority (SFDA), recently engaged in fruitful discussions with officials from prominent U.S. healthcare companies specializing in food, drugs, medical devices, and equipment.
The meetings went over the roles and responsibilities of SFDA and its support of the private sector in light of the promising development opportunities available in the Kingdom of Saudi Arabia, primarily those related to the localization of the drug and pharmaceutical industries as well as food safety and genetics technologies sectors.
The meetings were held on the sidelines of the 25th session of the International Medical Device Regulators Forum (IMDRF) as part of the SFDA’s endeavor to enhance investment opportunities and engage in the know-how dynamics of the industry and the challenges facing investors and the business community.
The collaborative efforts between SFDA and U.S. healthcare companies reflect a shared commitment to driving progress and innovation in the healthcare landscape. As Saudi Arabia continues to prioritize healthcare development and diversification, partnerships with leading global players are poised to play a pivotal role in shaping the future of the industry.
